Ambeed.cn

首页 / / / / Montelukast Sodium

孟鲁司特钠 /Montelukast Sodium {[allProObj[0].p_purity_real_show]}

货号:A232574 同义名: 孟鲁司特钠 水合物 / MK0476;Montelukast (sodium salt)

Montelukast Sodium is a potent, selective and competitive LTR1 antagonist with IC50 value < 5 nM, possesssing anti-inflammatory and bronchodilating activities.

Montelukast Sodium 化学结构 CAS号:151767-02-1
Montelukast Sodium 化学结构
CAS号:151767-02-1
Montelukast Sodium 3D分子结构
CAS号:151767-02-1
Montelukast Sodium 化学结构 CAS号:151767-02-1
Montelukast Sodium 3D分子结构 CAS号:151767-02-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Montelukast Sodium 纯度/质量文件 产品仅供科研

货号:A232574 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell Host Microbe, 2024. Ambeed. [ A163338 ]
Cancer Res., 2024. Ambeed. [ A295334 ]
J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]
J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]
JBC, 2024, 107935. Ambeed. [ A194396 ]
更多 >
产品名称 LTR 其他靶点 纯度
Montelukast Sodium 98%
MK571 98%
Zafirlukast 99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Montelukast Sodium 生物活性

靶点
  • LTR

描述 Cysteinyl leukotrienes (CysLTs, including LTC4, LTD4, and LTE4), mainly produced by eosinophils, mast cells, and macrophages in response to a variety of stimuli activating arachidonate 5-lipoxygenase pathway, are important inflammatory mediators. CysLT1 receptor (LTR1) expresses in human lung smooth muscle cells, lung macrophages, most peripheral blood eosinophils and pregranulocytic CD34+ cells, and in subsets of monocytes and B lymphocytes. Montelukast Sodium is a potent, selective and competitive LTR1 antagonist with IC50 value < 5 nM and are currently used in the treatment of asthma. Nonsmoking patients with asthma treated with Montelukast Sodium(200mg, three times daily for 10 1/3 days) showed improvements in FEV1, compared with placebo-treated patients[5]. In C57BL/6 mice with asthma induced by chronic exposure to ovalbumin, Montelukast (6 mg/kg, once daily for 20 days) treatment significantly suppressed the increased eosinophils in bronchoalveolar lavage (BAL) fluid and lung tissue, and increased IL-5 level in BAL fluid in models[6]. It was also proved that Montelukast inhibited the diabetes-induced capillary and neuronal degeneration in streptozotocin-induced diabetes mouse model[7].
作用机制 Montelukast Sodium is a potent competing ligand for high affinity [3H]LTD4 specific binding.

Montelukast Sodium 动物研究

Dose Rat: 0.2 mg/kg - 20 mg/kg[3] (i.g.)
Administration i.g.
Pharmacokinetics
Animal Mice[4] Rats[4] Monkeys[4]
Dose 50 mg/kg 25 mg/kg 25 mg/kg
Administration p.o. p.o. p.o.
F 0.61 34.2 ± 13.8% 52.8 ± 25.2%
T1/2 176 ± 122 min 457 ± 55.9 min
Tmax 60 min 37.5 ± 8.66 min 67.5 ± 35.7 min
Cmax 14.4 μg/ml 2.82 ± 1.61 μg/ml 21.6 ± 4.32 μg/ml
AUC0→∞ 2411 μg·min/ml 580 ± 235 μg·min/ml 5360 ± 2557 μg·min/ml

Montelukast Sodium 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02110654 Sinusitis Nas... 展开 >>al Polyps Asthma 收起 << Phase 4 Unknown June 2016 China, Guangdong ... 展开 >> the first affiliated hospital, Sun Yat-sen University Not yet recruiting Guangzhou, Guangdong, China, 510080 Contact: Fenghong Chen, doctor    02086013560170816    chfhong@mail.sysu.edu.cn    Principal Investigator: jianbo Shi, doctor 收起 <<
NCT00504946 Asthma Phase 3 Completed - Poland ... 展开 >> Department of Pediatrics and Allergy, Medical University of Lodz Lodz, Poland Lodz, Poland, 93-513 收起 <<
NCT00398151 Asthma Phase 3 Completed - -

Montelukast Sodium 参考文献

[1]Mullol J, Callejas FB, et al. Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival. J Biol Regul Homeost Agents. 2010 Oct-Dec;24(4):403-11.

[2]Zhang YJ, Zhang L, et al. Montelukast modulates lung CysLT(1) receptor expression and eosinophilic inflammation in asthmatic mice. Acta Pharmacol Sin. 2004 Oct;25(10):1341-6.

[3]Wu S, Zhu X, et al. The protective role of montelukast against intestinal ischemia-reperfusion injury in rats. Sci Rep. 2015 Oct 26;5:15787.

[4]Montelukast

[5]Reiss TF, Altman LC, Chervinsky P, Bewtra A, Stricker WE, Noonan GP, Kundu S, Zhang J. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol. 1996 Sep;98(3):528-34. doi: 10.1016/s0091-6749(96)70086-6. PMID: 8828530.

[6]Zhang YJ, Zhang L, Wang SB, Shen HH, Wei EQ. Montelukast modulates lung CysLT(1) receptor expression and eosinophilic inflammation in asthmatic mice. Acta Pharmacol Sin. 2004 Oct;25(10):1341-6. PMID: 15456537.

[7]Bapputty R, Talahalli R, Zarini S, Samuels I, Murphy R, Gubitosi-Klug R. Montelukast Prevents Early Diabetic Retinopathy in Mice. Diabetes. 2019 Oct;68(10):2004-2015. doi: 10.2337/db19-0026. Epub 2019 Jul 26. PMID: 31350303; PMCID: PMC6754245.

Montelukast Sodium 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.64mL

0.33mL

0.16mL

8.22mL

1.64mL

0.82mL

16.44mL

3.29mL

1.64mL

Montelukast Sodium 技术信息

CAS号151767-02-1
分子式C35H35ClNNaO3S
分子量 608.165
别名 孟鲁司特钠 水合物 ;MK0476;Montelukast (sodium salt);MK-476
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,Room temperature

溶解度

DMSO: 50 mg/mL(82.21 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 50 mg/mL(82.21 mM)

动物实验配方

PO 0.5% CMC-Na 17 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。